Literature DB >> 2242019

Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.

R L Bai1, G R Pettit, E Hamel.   

Abstract

Eighteen configurational isomers of the antimitotic peptide dolastatin 10 (Bai et al., Biochem Pharmacol 39: 1941-1949, 1990) derived from Dolabella auricularia, together with segments obtained as precursors in its synthesis (Pettit et al., J Am Chem Soc 111: 5463-5465, 1989), were examined as inhibitors of tubulin polymerization and as inhibitors of growth of L1210 murine leukemia cells in culture. Dolastatin 10 consists of four amino acids (in order from the amino terminus: dolavaline, valine, dolaisoleucine, and dolaproine), three unique to D. auricularia, linked to an unusual primary amine (dolaphenine, probably derived from phenylalanine) at what would otherwise be its carboxyl terminus. Dolastatin 10 has nine asymmetric carbon atoms, and available isomers included alternate configurations at five positions (positions 9 and 10 in the dolaproine moiety and positions 18, 19 and 19a in the dolaisoleucine moiety). For tubulin polymerization, only alterations at positions 18 and 19 resulted in loss of inhibitory activity of the isomer. In addition, a tripeptide containing dolavaline, valine and dolaisoleucine with all asymmetric carbons identical configurationally to those in dolastatin 10 was found to be about 30% as effective as dolastatin 10 in inhibiting tubulin polymerization. Cytotoxic effects were much more sensitive to alterations in the dolastatin 10 structure. The only modification which did not lead to reduced cytotoxicity was reversal of configuration at position 19a in the dolaisoleucine moiety. Both this isomer and dolastatin 10 had IC50 values of less than 1 nM. Several other isomers had IC50 values with the L1210 cells in the range of 30-90 nM, but these did not correlate well with their inhibitory effects on tubulin polymerization. The tripeptide effective as an inhibitor of tubulin polymerization had no activity against the L1210 cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242019     DOI: 10.1016/0006-2952(90)90367-t

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

1.  Structural insight into the inhibition of tubulin by vinca domain peptide ligands.

Authors:  Anthony Cormier; Matthieu Marchand; Raimond B G Ravelli; Marcel Knossow; Benoît Gigant
Journal:  EMBO Rep       Date:  2008-09-12       Impact factor: 8.807

Review 2.  Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Authors:  Satish K Singh; Donna L Luisi; Roger H Pak
Journal:  Pharm Res       Date:  2015-05-19       Impact factor: 4.200

3.  Discovery of Dolastatinol: A Synthetic Analog of Dolastatin 10 and Low Nanomolar Inhibitor of Tubulin Polymerization.

Authors:  Hodaya Gutman; Andrii Bazylevich; Chandrashekhar Prasad; Ortal Dorfman; Arkadi Hesin; Vered Marks; Leonid Patsenker; Gary Gellerman
Journal:  ACS Med Chem Lett       Date:  2021-09-07       Impact factor: 4.632

4.  Conformational behaviour of the antineoplastic peptide dolastatin-10 and of two mutated derivatives.

Authors:  P Fantucci; T Marino; N Russo; A M Villa
Journal:  J Comput Aided Mol Des       Date:  1995-10       Impact factor: 3.686

Review 5.  Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.

Authors:  Yu-Jie Wang; Yu-Yan Li; Xiao-Yu Liu; Xiao-Ling Lu; Xin Cao; Bing-Hua Jiao
Journal:  Mar Drugs       Date:  2017-01-13       Impact factor: 5.118

6.  Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin αV β3.

Authors:  André Raposo Moreira Dias; Lizeth Bodero; Ana Martins; Daniela Arosio; Silvia Gazzola; Laura Belvisi; Luca Pignataro; Christian Steinkühler; Alberto Dal Corso; Cesare Gennari; Umberto Piarulli
Journal:  ChemMedChem       Date:  2019-03-22       Impact factor: 3.466

Review 7.  Molecular Delivery of Cytotoxic Agents via Integrin Activation.

Authors:  Martina Cirillo; Daria Giacomini
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

Review 8.  From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds.

Authors:  Rita De Sanctis; Flavia Jacobs; Chiara Benvenuti; Mariangela Gaudio; Raul Franceschini; Richard Tancredi; Paolo Pedrazzoli; Armando Santoro; Alberto Zambelli
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

Review 9.  Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.

Authors:  Eunhee G Kim; Kristine M Kim
Journal:  Biomol Ther (Seoul)       Date:  2015-11-01       Impact factor: 4.634

Review 10.  Marine Antitumor Peptide Dolastatin 10: Biological Activity, Structural Modification and Synthetic Chemistry.

Authors:  Gang Gao; Yanbing Wang; Huiming Hua; Dahong Li; Chunlan Tang
Journal:  Mar Drugs       Date:  2021-06-24       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.